Article
Tom Caravela
The BURN: How to Become a TOP Performer & Excel at the HIGHEST Levels
Summary
In this episode, Tom Caravela is joined by Ben Newman, who delves into the concept of "the burn" and its role in maintaining motivation and purpose. Ben shares insights on the importance of showing up consistently, even after achieving success, and highlights the significance of setting daily standards to drive progress. The discussion includes strategies for reframing mindsets to focus on solutions and offers tips for career advancement and differentiation. Ben outlines the attributes of top performers and provides advice on overcoming daily excuses. The episode concludes with Ben's final thoughts and a call to action for listeners to subscribe and engage.
This episode features Ben Newman, Peak Performance Coach, Best Selling Author, TOP 50 Global Speaker and Host of the THE BURN Podcast. Ben discusses how to become a top performer and excel at the highest levels. You can learn more about Ben at https://bennewman.net/
Ben shares….
👉 What he means by THE BURN and how we find it
👉 How to handles the ups and downs of life
👉 What makes a top performer
👉 How you can stand out in your career and get noticed
👉 What it takes to find consistency
Peak Performance, Ben Newman, Motivation Strategies, Career Advancement, Top Performers
Related Topics
You May Also Like
Tom Caravela
Podcast
MSL Talk: Tom Caravela, John Pracyk
Unlocking Success: The Power of Continuous Learning
Podcast
MSL Talk: Tom Caravela
From Medically Impossible to Medical MIRACLE
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS